US 12,215,144 B2
Acute treatment and rapid treatment of headache using anti-CGRP antibodies
Roger K. Cady, Bothell, WA (US); Jeffrey T.L. Smith, Dublin (IE); Joseph Hirman, Bothell, WA (US); Barbara Schaeffler, Bothell, WA (US); and Lahar Mehta, Valby (DK)
Assigned to H. LUNDBECK A/S, Valby (DK)
Filed by H. LUNDBECK A/S, Valby (DK)
Filed on Mar. 19, 2024, as Appl. No. 18/609,223.
Application 18/609,223 is a division of application No. 18/173,116, filed on Feb. 23, 2023.
Application 18/173,116 is a division of application No. 16/736,925, filed on Jan. 8, 2020, granted, now 11,639,380, issued on May 2, 2023.
Claims priority of provisional application 62/872,989, filed on Jul. 11, 2019.
Claims priority of provisional application 62/842,162, filed on May 2, 2019.
Claims priority of provisional application 62/789,828, filed on Jan. 8, 2019.
Prior Publication US 2024/0270832 A1, Aug. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 9/00 (2006.01); A61K 31/4172 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61P 25/06 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 9/0019 (2013.01); A61K 31/4172 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61P 25/06 (2018.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01)] 31 Claims
 
1. A method of acute treatment of migraine in a patient in need thereof, the method comprising intravenously administering to the patient:
(A) about 100 mg or about 300 mg of a monoclonal antibody comprising:
(a) a variable light chain polypeptide comprising light chain complementary determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224, SEQ ID NO: 226, and SEQ ID NO: 228, respectively, and
(b) a variable heavy chain polypeptide comprising heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204, SEQ ID NO: 206, and SEQ ID NO: 208, respectively; and
(B) one or more acute migraine medications,
wherein the administering begins while the patient is experiencing a headache, and wherein the administering is followed by preventive treatment once every three months using about 100 mg or about 300 mg of said monoclonal antibody.